Author

Gayanie Ong

Observed name: Gayanie S. Ong

Institution: Ohara Inc. (Japan)

Observed institutions: NYU Langone Health, Ohara Inc. (Japan)

OpenAlex ID: A5113033853

EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

2024 · Salman Rafi Punekar, J. Randolph Hecht, et al. · Journal of Clinical Oncology · 10

636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

2023 · Diane M Simeone, J Randolph Hecht, et al. · Regular and Young Investigator Award Abstracts · 3

Abstract CT186: EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

2025 · Julian R. Molina, Antonious Hazim, et al. · Cancer Research · 1

627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

2024 · Julian R Molina, Antonious Hazim, et al. · Regular and Young Investigator Award Abstracts

Works count: 4

Citation count: 14

H-index: 2

I10-index: 1